ADVERTISEMENT

Covishield Produces More Antibodies Than Covaxin: Study

Of the 425 Covishield and 90 Covaxin recipients, 98.1 percent and 80.0 percent respectively, showed seropositivity.

Published
<div class="paragraphs"><p>Preliminary results of the study find that seropositivity and antibody production is higher in the Covishield COVI-19 vaccine as compared to Covaxin.</p></div>
i

A latest study has found that both vaccines, Covishield and Covaxin elicited good immune response after two doses, although seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield as compared to Covaxin.

The study is titled, Antibody Response after Second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study published in MedRxiv.

The results found that among the 515 HCW (305 Male, 210 Female), 95.0 percent showed seropositivity after two doses of both vaccines.

Of the 425 Covishield and 90 Covaxin recipients, 98.1 percent and 80.0 percent respectively, showed seropositivity.

However, both seropositivity rate and median (IQR) rise in anti-spike antibody was significantly higher in Covishield vs. Covaxin recipient (98.1 vs. 80.0 per cent; 127.0 vs. 53 AU/mL; both p<0.001), the study said.

ADVERTISEMENT

This difference persisted in 457 SARS-CoV-2 naive cohorts and propensity-matched (age, sex and BMI) analysis of 116 cohorts.

While no difference was observed in relation to sex, BMI, blood group and any comorbidities; people with age more than 60 years or those with type 2 diabetes had a significantly lower seropositivity rates.

Both vaccine recipients had similar solicited mild to moderate adverse events and none had severe or unsolicited side effects.

In SARS-CoV-2 naive cohorts, sex, presence of comorbidities, and vaccine type were independent predictors of antibody positivity rate in multiple logistic regression analysis. Conclusions:

"Both vaccines elicited good immune response after two doses, although seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield compared to Covaxin arm."
The study authors

A pan-India, cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study was conducted that measured SARS-CoV-2 anti-spike binding antibody quantitatively, 21 days or more after the first and second dose of two vaccines in both severe acute respiratory syndrome (SARS-CoV-2) naive and recovered HCW.

Primary aim was to analyze antibody response (seropositivity rate and median [inter-quartile range, IQR] antibody titre) following each dose of both vaccines and its correlation to age, sex, blood group, body mass index (BMI) and comorbidities.

(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT)

(Subscribe to FIT on Telegram)

ADVERTISEMENT
Stay Up On Your Health

Subscribe To Our Daily Newsletter Now.

Join over 120,000 subscribers!
ADVERTISEMENT